Patrice Y. Neese

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2003 · 321 citations

Medicine, Immunology, Oncology +17

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Craig L. Slingluff, Galina V. Yamshchikov, Patrice Y. Neese et al. · PubMed · 2001 · 229 citations

Medicine, Immunology, Oncology +17

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

Craig L. Slingluff, Gina R. Petroni, Kimberly A. Chianese‐Bullock et al. · Clinical Cancer Research · 2007 · 163 citations · Full text

Medicine, Immunology, Oncology +17

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2004 · 146 citations · Full text

Life Sciences, Immunology, Oncology +17

MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma

Kimberly A. Chianese‐Bullock, Jennifer Pressley, Courtney F. Garbee et al. · The Journal of Immunology · 2005 · 125 citations

Medicine, Immunology, Oncology +17